Male or female subjects ≥18 years old

Subjects must have histological diagnosis of locally advanced (primary or recurrent) or metastatic solid tumour of the kind listed below that is not amenable for treatment with curative intent, e.g.:

Part 1:

Mesothelioma

Epithelioid hemangioendothelioma (EHE)

Cholangiocarcinoma (CCA)

Head and neck squamous cell carcinoma (HNSCC)

Non‑small cell lung carcinoma (NSCLC)

Colorectal cancer (CRC)

Hepatocellular carcinoma (HCC)

Castration‑resistant prostate cancer (CRPC)

Meningioma

Other solid tumours with local data showing NF2 or LATS1/LATS2 loss‑of‑function alterations or YAP/TAZ fusions

Other solid tumours based on emerging scientific data per sponsor decision

Subjects must be in need of systemic treatment for their cancer and to either be refractory to or have progressed on, are intolerant to, or are not otherwise a candidate, in the opinion of the investigator, for any of the currently available established therapies (reasons of unsuitability of standard of care treatments to be recorded).

Part 2 only: Subjects must have measurable disease by response evaluation criteria in solid tumours (response evaluation criteria in solid tumors - RECIST) v. 1.1 (modified RECIST for malignant pleural mesothelioma - MPM).

Part 2 only: A fresh or recent (taken up to 1 year ago) primary tumour tissue sample from a diagnostic biopsy/surgery or a tumour biopsy taken from a metastasis must be available; exemptions possible by the sponsor's decision.

Performance status 0-1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.

Life expectancy of >12 weeks.

Willing and able to comply with all aspects of the protocol.

Provide written informed consent (IC; or witness consent) prior to any study-specific screening procedures.

Active malignancy within 2 years, except adequately treated basal/squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of cervix or breast.

Anti‑cancer therapy within 2 weeks (chemotherapy, immunotherapy, investigational agents) or unresolved CTCAE Grade ≥2 toxicities (except specified conditions). LHRH agonists/antagonists allowed.

Definitive radiotherapy <4 weeks, palliative radiotherapy <2 weeks, or radiopharmaceuticals <8 weeks before dosing.

Symptomatic or untreated brain/subdural metastases.

Known HIV infection.

Active infection requiring therapy, including HBV or HCV.

Major surgery <4 weeks or minor surgery <1 week prior to dosing without recovery.

Immunosuppressive systemic therapy (>10 mg/day prednisone equivalent) within 2 weeks.

Inability to take oral medication, malabsorption, or uncontrolled gastrointestinal conditions affecting absorption.

Live or live‑attenuated vaccines within 28 days.

Clinically significant ECG abnormalities, prolonged QTc (>470 ms), torsade de pointes risk, or QT‑prolonging medications.

Significant cardiovascular disease (NYHA III–IV HF, uncontrolled hypertension, recent MI/stroke, LVEF <50%, significant arrhythmia) within 6 months.

Pregnant or breastfeeding women; inadequate pregnancy testing.

Inadequate contraception compliance (male or female subjects).

Renal impairment: UACR ≥3 mg/mmol, eGFR ≤60 ml/min/1.73 m², ESRD, dialysis, transplant, or nephropathy.

Hepatic impairment: bilirubin ≥1.5×ULN (≥3×ULN for Gilbert’s), AST/ALT ≥3×ULN (≥5×ULN with liver metastases), albumin ≤30 g/L.

INR >1.5×ULN unless therapeutically anticoagulated.

Haemoglobin <10 g/dL, ANC <1500/µL, or platelets <100,000/µL.

Any serious medical condition increasing risk or interfering with participation.

Prior treatment with TEAD inhibitors.